Crystalline forms of therapeutic compounds and uses thereof
Described herein are crystalline forms of Compound 1 useful for the prevention and treatment of angiogenic ocular conditions; methods of treating a disease comprising; processes for preparing; and kits comprising, the same.
1. A method of treating a disease comprising administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising a crystalline form of Compound 1:
wherein the crystalline form has an X-ray powder diffraction (XRPD) pattern comprising peaks at 8.5-9.5 degrees 2θ, 18-19 degrees 2θ, 19-19.5 degrees 2θ, and 25.0-25.5 degrees 2θ; and
wherein the disease is a proliferative disease, cancer, or an ocular disease.
2. The method of claim 1 , wherein the crystalline form is a hydrate.
3. The method of claim 1 , wherein the pharmaceutical composition comprises the crystalline form of claim 1 and a pharmaceutically acceptable carrier.
4. The method of claim 3 , wherein the pharmaceutical composition is suitable for topical administration.
5. The method of claim 3 , wherein the pharmaceutical composition is suitable for injection.
6. The method of claim 3 , wherein the pharmaceutical composition is suitable for delivery to the eye.
7. The method of claim 1 , wherein the disease is a proliferative disease.
8. The method of claim 1 , wherein the disease is cancer.
9. The method of claim 1 , wherein the disease is an ocular disease.
10. The method of claim 9 , wherein the disease is retinopathy.
11. The method of claim 9 , wherein the disease is age-related macular degeneration (AMD).
12. The method of claim 9 , wherein the disease is corneal neovascularization.
13. A method of inhibiting growth factor signaling comprising administering to a subject a therapeutically effective amount of a pharmaceutical composition comprising a crystalline form of Compound 1:
wherein the crystalline form has an X-ray powder diffraction (XRPD) pattern comprising peaks at 8.5-9.5 degrees 2θ, 18-19 degrees 2θ, 19-19.5 degrees 2θ, and 25.0-25.5 degrees 2θ.
14. The method of claim 13 , wherein the crystalline form is a hydrate.
15. The method of claim 13 , wherein the pharmaceutical composition comprises the crystalline form of claim 1 and a pharmaceutically acceptable carrier.
16. The method of claim 15 , wherein the pharmaceutical composition is suitable for topical administration.
17. The method of claim 15 , wherein the pharmaceutical composition is suitable for injection.
18. The method of claim 15 , wherein the pharmaceutical composition is suitable for delivery to the eye.
19. The method of claim 15 , wherein the growth factor signaling is associated with an ocular disease.